Synthemax cuts hESC production cost say Geron and Corning
New Synthemax synthetic growth matrix promises improved scalability for large-scale hESC production which, say developers Geron and Corning, will cut cost of cell therapy manufacture.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs